No Prescription |
 |
 | ||
|
Premia Continuous Premphase |
|
| ||
No Prescription » Prescription Drugs 13 » Premia Continuous Premphase This medication is used to reduce menopause symptoms. It helps reduce episodes of flushing and sweating of the upper body and face commonly called hot flashes. It also helps treat dryness itching and burning around the vagina. These symptoms occur when a woman's body no longer makes the usual amount of female hormone (estrogen). This medication is a combination of 2 types of female hormones: estrogen (conjugated estrogens) and a progestin (medroxyprogesterone). A progestin is added to estrogen replacement therapy to reduce the risk of cancer of the uterus. A woman who has had her uterus removed does not need progestin and should not be treated with this combination medication.If you need treatment only for vaginal menopause symptoms products applied directly inside the vagina should be considered before medications that are taken by mouth absorbed through the skin or injected.This medication may also be used to prevent bone loss (osteoporosis) in people at high risk who cannot take other drugs that are safe and effective to prevent or treat bone loss (e.g. raloxifene bisphosphonates such as alendronate). These medicines should be considered for use before estrogen/progestin HRT therapy for osteoporosis. Buy Premia Continuous Premphase and other Prescription Drugs 13 products online at Medstore. Buy Online at Medstore - Click Here!
About Premia Continuous Premphase: Product Type: Prescription Drugs 13 Premia Continuous ( Premphase Prempro Generic Conj.Estrogen & Medroxyprogesterone ) Premia Continuous (Premphase Prempro Generic Conj.Estrogen & Medroxyprogesterone) Premphase Prempro Generic Conj.Estrogen & Medroxyprogesterone 0.625/2.5mg 28 tablets 0.625/2.5mg 56(2 x 28) Tablets 0.625/2.5mg 112(4 x 28) Tablets 0.625mg/5mg 28 Tablets 0.625mg/5mg 84 (3 x 28) Tablets 0.625mg/5mg 168 (6 x 28) Tablets Premphase Prempro Generic Conj.Estrogen & Medroxyprogesterone Premia Continuous
View more Prescription Drugs 13 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
